Prognostic significance of primary-tumor extension, stage and grade of nuclear differentiation in patients with renal cell carcinoma

Surgery remains the preferred therapy for renal cell carcinoma. The various adjunctive or complementary therapies currently yield disappointing results. Identifying reliable prognostic factors could help in selecting patients most likely to benefit from postoperative adjuvant therapies. We reviewed the surgical records of 78 patients who had undergone radical nephrectomy with lymphadenectomy for renal cell carcinoma, matched for type of operation and histology. According to staging (TNM), 5.1% of the patients were classified as stage I, 51.3% as stage II, 29.5% as stage III and 14.5% as stage IV. Of the 78 patients 40 were T 2 N 0 and 21 T 3 aN 0 . Tumor grading showed that 39.7% of the patients had well-differentiated tumors(G 1 ), 41.1% moderately-differentiated (G 2 ), and 19.2% poorly-differentiated tumors (G 3 ). Overall actuarial survival at 5 and 10 years was 100% for stage I; 91.3% at 5 years and 83.1% at 10 years for stage II; 45.5% and 34.1% for stage III; and 29.1% and nil for stage IV (stage II vs stage III p = 0.0001). Patients with tumors confined to the kidney (pT 2 N 0 ) had better 5- and 10-year survival rates than patients with tumors infiltrating the perirenal fat (pT 3 a N 0 ) (p = 0.000006). Survival differed according to nuclear grading (G 1 vs G 3 ; p = 0.000005; G 2 vs G 3 ; p = 0.0009). In conclusion our review identified tumor stage, primary-tumor extension, and the grade of nuclear differentiation as reliable prognostic factors in patients with renal cell carcinomas.